我的生活+的主要目标之一是帮助人们预防新的HIV和其他STI,丙型肝炎和结核病病历的产生。

该应用程序有助于建立医生和HIV感染者之间的匿名沟通。 它可以让您创建简单易行的服药时间表,并设置隐藏和个性化的提醒。

返回
17 二月 2019, 08:10
7457

EMA approved two new doravirin-based ARV drugs

EMA approved two new doravirin-based ARV drugs - 图片 1

The European Medicines Agency (EMA) has approved the use of drugs for the treatment of HIV Delstrigo and Pifeltro. As previously reported, the FDA issued permission for their marketing in the United States at the end of August last year.

As follows from the data published in the EMA Human Mtdicines Highlights monthly, the antiretroviral drug Delstrigo (doravirin, 100 mg / tenofovir disoproxil fumarate, 300 mg / lamivudine, 300 mg) of the pharmaceutical company MSD is intended for the treatment of HIV-1 in adults. The use of the drug is recommended in the format of "one tablet once a day." The drug is not suitable for HIV-infected patients who are resistant to lamivudine, TDF, or drugs of the same class as doravirin (non-nucleoside reverse transcriptase inhibitors).

Pifeltro (doravirin, 100 mg) is an antiviral agent intended for the treatment of adults with HIV-1, and recommended for use in combination with other ART.

We add that the US Food and Drug Administration (FDA) has decided to issue marketing permits for Delstrigo and Pifeltro at the end of August 2018, two months earlier than originally planned.

作者: Marina Shegay

在社交媒体上分享